Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study

TY - JOUR

T1 - Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention

T2 - A Single-Centre Observational Study

AU - Thim, Troels

AU - Jakobsen, Lars

AU - Jensen, Rebekka Vibjerg

AU - Støttrup, Nicolaj

AU - Eftekhari, Ashkan

AU - Grove, Erik Lerkevang

AU - Larsen, Sanne Bøjet

AU - Sørensen, Jacob Thorsted

AU - Carstensen, Steen

AU - Amiri, Sahar

AU - Veien, Karsten Tange

AU - Christiansen, Evald Høj

AU - Terkelsen, Christian Juhl

AU - Maeng, Michael

AU - Kristensen, Steen Dalby

PY - 2023

Y1 - 2023

N2 - BACKGROUND: Reversible P2Y12 inhibition can be obtained with cangrelor administered intravenously. More experience with cangrelor use in acute PCI with unknown bleeding risk is needed.OBJECTIVES: To describe real-world use of cangrelor including patient and procedure characteristics and patient outcomes.METHODS: We performed a single-centre, retrospective, and observational study including all patients treated with cangrelor in relation to percutaneous coronary intervention at Aarhus University Hospital during the years 2016, 2017, and 2018. We recorded procedure indication and priority, the indications for cangrelor use, and patient outcomes within the first 48 hours after initiation of cangrelor treatment.RESULTS: We treated 991 patients with cangrelor in the study period. Of these, 869 (87.7%) had an acute procedure priority. Among acute procedures, patients were mainly treated for STEMI (n = 723) and the remaining were treated for cardiac arrest and acute heart failure. Use of oral P2Y12 inhibitors prior to percutaneous coronary intervention was rare. Fatal bleeding events (n = 6) were only observed among patients undergoing acute procedures. Stent thrombosis was observed in two patients receiving acute treatment for STEMI. Thus, cangrelor can be used in relation to PCI under acute circumstances with advantages in terms of clinical management. The benefits and risks, in terms of patient outcomes, should ideally be assessed in randomized trials.

AB - BACKGROUND: Reversible P2Y12 inhibition can be obtained with cangrelor administered intravenously. More experience with cangrelor use in acute PCI with unknown bleeding risk is needed.OBJECTIVES: To describe real-world use of cangrelor including patient and procedure characteristics and patient outcomes.METHODS: We performed a single-centre, retrospective, and observational study including all patients treated with cangrelor in relation to percutaneous coronary intervention at Aarhus University Hospital during the years 2016, 2017, and 2018. We recorded procedure indication and priority, the indications for cangrelor use, and patient outcomes within the first 48 hours after initiation of cangrelor treatment.RESULTS: We treated 991 patients with cangrelor in the study period. Of these, 869 (87.7%) had an acute procedure priority. Among acute procedures, patients were mainly treated for STEMI (n = 723) and the remaining were treated for cardiac arrest and acute heart failure. Use of oral P2Y12 inhibitors prior to percutaneous coronary intervention was rare. Fatal bleeding events (n = 6) were only observed among patients undergoing acute procedures. Stent thrombosis was observed in two patients receiving acute treatment for STEMI. Thus, cangrelor can be used in relation to PCI under acute circumstances with advantages in terms of clinical management. The benefits and risks, in terms of patient outcomes, should ideally be assessed in randomized trials.

UR - http://www.scopus.com/inward/record.url?scp=85163953367&partnerID=8YFLogxK

U2 - 10.1155/2023/3197512

DO - 10.1155/2023/3197512

M3 - Journal article

C2 - 37361000

SN - 2090-8016

VL - 2023

JO - Cardiology Research and Practice

JF - Cardiology Research and Practice

M1 - 3197512

ER -